12. STOCK OPTIONS AND WARRANTS	9 Months Ended
Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK OPTIONS AND WARRANTS	Stock Options There were no stock options issued during the nine months ended September 30, 2017. During the nine months ended September 30, 2017, the Company recorded stock option based compensation of $118,671 related to prior grants. As of September 30, 2017, there is $73,309 of unrecognized stock option based compensation expense that will be recognized over the next three years. Warrants In connection with the funding of a convertible note payable, and as of September 18, 2017, the Company issued 2,500,000 common stock purchase warrants each with a $0.15 exercise price (See Note 7). In connection with a Draw Down of a convertible line of credit, as of September 26, 2017, the Company issued 1,416,667 common stock purchase warrants each with a $0.15 exercise price (See Note 8). Pursuant to a private placement, the Company is obligated to issue 15,000 warrants as an offering cost to a third party, each with a 5 year term and a strike price of $0.15 per share, at the close of the private placement offering. There will be no accounting effect for the issuance of these warrants as their fair value will be charged to additional paid-in-capital as an offering cost and offset by a credit to additional paid-in-capital for their fair value when issuing these warrants (See Note 11 and Note 14).

12. STOCK OPTIONS AND WARRANTS

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Options

There were no stock options issued during the nine months ended September 30, 2017.

During the nine months ended September 30, 2017, the Company recorded stock option based compensation of $118,671 related to prior grants. As of September 30, 2017, there is $73,309 of unrecognized stock option based compensation expense that will be recognized over the next three years.

Warrants

In connection with the funding of a convertible note payable, and as of September 18, 2017, the Company issued 2,500,000 common stock purchase warrants each with a $0.15 exercise price (See Note 7).

In connection with a Draw Down of a convertible line of credit, as of September 26, 2017, the Company issued 1,416,667 common stock purchase warrants each with a $0.15 exercise price (See Note 8).

Pursuant to a private placement, the Company is obligated to issue 15,000 warrants as an offering cost to a third party, each with a 5 year term and a strike price of $0.15 per share, at the close of the private placement offering. There will be no accounting effect for the issuance of these warrants as their fair value will be charged to additional paid-in-capital as an offering cost and offset by a credit to additional paid-in-capital for their fair value when issuing these warrants (See Note 11 and Note 14).